Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Nov 20, 2022
Date Accepted: Feb 26, 2024
Effects of planned online educational intervention based on the health belief model for ischemic stroke patients in promoting secondary prevention during the COVID-19 lockdown in China: A quasi-experimental study
ABSTRACT
Background:
Some common modified vascular risk factors remain poorly controlled among stroke survivors, and educational programs may help improve these conditions.
Objective:
This study aimed to evaluate the effect of planned online educational intervention based on the health belief model (HBM) for promoting secondary prevention in ischemic stroke patients.
Methods:
An evaluation-blinded quasi-experimental trial with a historical control group was conducted. The control group received routine health management. The intervention group received six additional sessions within 3 months after discharge. The primary outcomes were changes in blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), haemoglobin A1c (HbA1c), and the proportion of patients achieving the treatment target. The secondary outcomes were medication adherence and disability.
Results:
In total, 315 first-ever stroke patients were analyzed. More patients in the intervention group had controlled BP (41.9% vs. 28.4%, adjusted odds ratio [aOR]: 1.93, P = 0.012), LDL-C (83.1% vs. 67.7%, aOR: 2.66, P = 0.001), and HbA1c (91.9% vs. 83.9%, aOR: 3.37, P = 0.035), and a significant decrease post-intervention in the systolic BP (adjusted β = -3.94, P = 0.021), LDL-C (adjusted β = -0.21, P = 0.008), and HbA1c (adjusted β = -0.27, P < 0.001) compared with control groups. Significant between-group differences were observed in medication adherence (79.4% vs. 63.2%, aOR: 2.31, P = 0.002), but not in favourable functional outcomes.
Conclusions:
An online education program based on HBM may be more effective than the current methods used to educate stroke patients on optimal vascular risk factors and medication adherence. Clinical Trial: The study protocol was registered in the Chinese Clinical Trial Registry (ChiCTR2000040804).
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.